These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1598944)

  • 41. Modern approach to the evaluation of combined effects of single-dose trials and clinical time-course studies, exemplified by combinations of pirenzepine and H2-receptor antagonists.
    Pöch G; Londong W
    Int J Clin Pharmacol Ther Toxicol; 1993 Oct; 31(10):483-8. PubMed ID: 8262686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis.
    Connelly JF
    Hosp Pharm; 1994 Nov; 29(11):992, 996-8, 1001. PubMed ID: 10138581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three surefire ways to cut your pharmacy costs.
    Capitation Manag Rep; 2001 Jan; 8(1):1-7. PubMed ID: 11209215
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy.
    Caldwell RD; Davis SK
    Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of peptic ulcer with ranitidine and cimetidine in a single nocturnal dose].
    Klinger J; Maggiolo P; Arteaga H; Goić A
    Rev Med Chil; 1987 Jul; 115(7):645-7. PubMed ID: 3331025
    [No Abstract]   [Full Text] [Related]  

  • 46. Randomized, prospective trial of cimetidine and ranitidine for control of intragastric pH in the critically ill.
    More DG; Raper RF; Munro IA; Watson CJ; Boutagy JS; Shenfield GM
    Surgery; 1985 Feb; 97(2):215-24. PubMed ID: 3881838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T; Hirata W; Higichi S
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. H2-antagonist dosing in the elderly based on renal function.
    Wallenberg BG; Caliendo TM
    Ann Pharmacother; 1992 Dec; 26(12):1595. PubMed ID: 1482819
    [No Abstract]   [Full Text] [Related]  

  • 49. Use of H2-receptor antagonists in children.
    Dimand RJ
    DICP; 1990 Nov; 24(11 Suppl):S42-6. PubMed ID: 2270695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Converting intravenous cimetidine and ranitidine therapy to oral therapy.
    Oh T; Rumsey K; Neistein J; Francko TG
    Am J Hosp Pharm; 1988 Jul; 45(7):1497. PubMed ID: 3414712
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of prolonged oral cimetidine, ranitidine, and famotidine therapy on antipyrine elimination.
    Sakaue H; Akamatsu K; Hirabayashi Y; Sasaki T; Nakanishi K; Okada S; Kanaoka M; Nishinobu M; Masumoto S; Ohta Y
    Clin Ther; 1987; 9(6):602-6. PubMed ID: 2894244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [H2-receptor antagonists. 10 questions--10 answers].
    Koelz HR
    Schweiz Rundsch Med Prax; 1984 Jun; 73(26):831-4. PubMed ID: 6089295
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-operative intramuscular ranitidine and cimetidine. Double blind comparative trial, effect on gastric pH and volume.
    Williams JG; Strunin L
    Anaesthesia; 1985 Mar; 40(3):242-5. PubMed ID: 3887977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How to tie a drug therapy improvement program to physician credentialing.
    Tse CS; Roecker W; Benitez M; Musabji M
    Hosp Formul; 1994 Sep; 29(9):646-50, 656. PubMed ID: 10137061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease.
    Bate CM; Richardson PD
    Pharmacoeconomics; 1993 Feb; 3(2):94-9. PubMed ID: 10146958
    [No Abstract]   [Full Text] [Related]  

  • 57. 'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?
    Garattini L; Padula A
    Appl Health Econ Health Policy; 2017 Feb; 15(1):1-3. PubMed ID: 26987647
    [No Abstract]   [Full Text] [Related]  

  • 58. Reducing polypharmacy in extended care.
    Hamdy RC; Moore SW; Whalen K; Donnelly JP; Compton R; Testerman F; Haulsee P; Hughes J
    South Med J; 1995 May; 88(5):534-8. PubMed ID: 7732442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Promoting use of a preferred histamine H2-receptor antagonist in managed care organizations.
    DeZearn K; Springer S; Benson D; Stephens C
    Am J Health Syst Pharm; 1996 Apr; 53(8):865-67. PubMed ID: 8728383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug use evaluation. Contributions to quality assurance and cost-containment.
    Navarro RP
    HMO Pract; 1989; 3(1):22-7. PubMed ID: 10292742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.